Arvinas, Inc.는 임상 단계 생명공학 기업으로, 질병 유발 단백질을 분해하는 치료제의 발굴, 개발 및 상업화에 주력하고 있습니다. 이 회사는 인체 고유의 자연적인 단백질 처리 시스템을 활용하여 질병 유발 단백질을 분해하고 제거하도록 설계된 프로테올리시스 표적 키메라(PROTAC) 표적 단백질 분해제를 개발하고 있습니다. 이 회사는 또한 다음과 같은 임상 개발 프로그램을 진행하고 있습니다: * ARV-102: 파킨슨병 및 진행성 핵상 마비와 같은 신경퇴행성 질환 치료를 위한 류신 풍부 반복 키나아제 2 (LRRK2) 단백질. * ARV-806: 췌장암, 대장암 및 비소세포폐암을 포함한 G12D 변이 암 치료를 위한 Kirsten 쥐 육종 G12D 단백질. * ARV-393: 재발성/불응성 비호지킨 림프종 (NHL) 치료를 위한 B세포 림프종 6 단백질. * AR
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
